Like other drugs, Restasis eye drops can cause mild to serious side effects. Keep reading to learn more. To learn more about some of these side effects, see the “Side effects explained ...

Restasis comes as an eye drop solution. The typical dosage is one drop per affected eye twice per day. Restasis belongs to a drug class called calcineurin inhibitors. This drug is available in a ...

Miebo eye drops represent a breakthrough for treating dry eye disease. However, their steep price can limit access for many ...

The U.S. Food and Drug Administration (FDA) is warning that people who use eye drops recalled over fungal contamination are risking vision damage and potential death. A recall notice shared to the ...

If you constantly deal with itchy or dry eyes, over-the-counter eye drops can help ease symptoms. Many things can cause your eyes to experience this discomfort. Wearing contact lenses, a dry ...

Many individuals choose to use castor oil as eye drops to lessen symptoms like dryness, redness, and swollenness in the eyes. One of the critical things to consider when purchasing castor oil eye ...

Eye drops are the most preferred drug delivery method in the ophthalmic market, yet developing eye drop formulations targeting the retina, located in the posterior segment of the eye, remains a ...

And with the holidays and “RHONY” reunion filming fast approaching, the Bravoleb tells Page Six Style she’s stocking up on must-haves like the Lumify Redness Reliever Eye Drops ($21 ...

The market encompasses various types of eye drops used for treating different ocular conditions, with a significant focus on prescription and over-the-counter products. Distribution channels include ...

Research on supplements for dry eyes is still evolving. Taking too much of some vitamins may cause negative side effects. You ...

BostonSight’s pilot study, published in Clinical Ophthalmology, explores the use of PROSE scleral lenses as a drug delivery system for cyclosporine 0.05% in treating dry eye disease, showing promising ...

But with Novartis failing to convince European regulators about the merits of Xiidra last year, and Allergan's ageing Restasis potentially ... a phase 3 trial for eye drops containing tivanisiran ...